Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tech Transfer Roundup: UM Ventures' Deal-Making Priority Is Flexibility

Executive Summary

Now providing seed and venture funding for some of its start-ups, University of Maryland's tech transfer has expanded its capabilities in recent years. Plus, our monthly roundup of private/public-sector transactions.

You may also be interested in...



Lilly Targets Aduhelm With Aggressive Plans For Donanemab In Alzheimer’s

Lilly plans a head-to-head study of donanemab versus Biogen’s Aduhelm to see which clears amyloid plaque better and has begun a rolling BLA toward accelerated approval of the Alzheimer’s drug.

Financing Quarterly Statistics, Q3 2021

For the third quarter of 2021, biopharmas brought in an aggregate $17.4bn in financing and device company fundraising totaled $3.4bn; while in vitro diagnostic firms and research tools players raised $2.5bn.

Metacrine’s Shift Means Further Attrition In FXR Agonist Class For NASH

Metacrine halts development of its FXR agonist compounds in NASH and turn its focus to inflammatory bowel disease. Firm plans Phase II ulcerative colitis study in 2022 with MET642.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC099268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel